If you have been reading about melanocortin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-10. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
== Personal life == On November 11, 1932, he married the socially connected Blanchette Ferry Hooker (1909–1992), who was to serve as chairman of the Asian Cultural Council from 1980 to 1990, and who established the Blanchette H. Rockefeller Fellowship Fund, in Japan. They had one son and three daughters:
==== 4.D Polysaccharide Synthase/Exporters ==== 4.D.1 The Putative Vectorial Glycosyl Polymerization (VGP) Family 4.D.2 The Glycosyl Transferase 2 (GT2) Family 4.D.3 The Glycan Glucosyl Transferase (OpgH) Family
== Dosimetry == Therapeutic PRRT treatments typically involve several gigabecquerels (GBq) of activity. Several radiopharmaceuticals allow simultaneous imaging and therapy, enabling precise dosimetric estimates to be made. For example, the bremsstrahlung emission from 90Y and gamma emissions from 177Lu can be detected by a gamma camera. In other cases, imaging can be performed by labelling a suitable radionuclide to the same peptide as used for therapy. Radionuclides that can be used for imaging include gallium-68, technetium-99m and fluorine-18. Currently used peptides can result in high kidney doses, as the radiopharmaceutical is retained for relatively long periods. Renal protection is therefore used in some cases, taking the form of alternative substances that reduce the uptake of the kidneys.
Endometrium: the mucosa of the uterus Gastric mucosa Intestinal mucosa Nasal mucosa Olfactory mucosa Oral mucosa Penile mucosa Respiratory mucosa Vaginal mucosa Frenulum of tongue Anal canal Conjunctiva
Sources: en.wikipedia.org
On 3 April 2007, The Boston Globe reported that tainted wheat gluten ended up in factories that produce food for human consumption. Then, on 19 April, federal U.S. officials said that they were investigating reports that Binzhou Futian rice protein had been used in hog feed, but declined to specify where. The California Department of Food and Agriculture placed American Hog Farm in Ceres, California under quarantine, after melamine was found in the urine of the hogs on the farm. According to California state officials, approximately 45 state residents consumed pork from hogs that had been fed melamine-contaminated feed. The FDA subsequently discovered that melamine was present in feed that had been given to hogs in California, New York, North Carolina, South Carolina, Utah, and possibly Ohio. In response, the FDA announced that, in addition to its existing practice of testing of wheat gluten and rice protein products for melamine, it would begin testing imported ingredients and finished products that contain cornmeal, corn gluten, rice bran and soy protein for the presence of melamine or cyanuric acid. The agency also subjected all vegetable proteins imported from China, intended for human or animal consumption, to detention without physical examination, beginning on 27 April. Finally, the FDA investigated domestic food manufacturers to ensure that no contaminated product was being used in foods intended for human use.
== Chromatography == Mikhail Tsvet invented chromatography in 1900 during his research on plant pigments. He used liquid-adsorption column chromatography with calcium carbonate as adsorbent and petrol ether/ethanol mixtures as eluent to separate chlorophylls and carotenoids. The method was described on 30 December 1901 at the XI Congress of Naturalists and Physicians (XI съезд естествоиспытателей и врачей) in St. Petersburg. The first printed description was in 1905, in the Proceedings of the Warsaw Society of Naturalists, biology section. He first used the term "chromatography" in print in 1906 in his two papers about chlorophyll in the German botanical journal, Berichte der Deutschen botanischen Gesellschaft. In 1907, he demonstrated his chromatograph for the German Botanical Society. For several reasons, Tsvet's work was long ignored: the violent political upheaval in Russia at the beginning of the 20th century, the fact that Tsvet originally published only in Russian (making his results largely inaccessible to western scientists), and an article denying Tsvet's findings. Richard Willstätter and Arthur Stoll tried to repeat Tsvet's experiments, but because they used an overly aggressive adsorbent (destroying the chlorophyll), they were not able to do so. They published their results, and Tsvet's chromatography method fell into obscurity. It was revived 10 years after his death thanks to Austrian biochemist Richard Kuhn and his student, German scientist Edgar Lederer as well as the work of A. J. Martin and R. L. Synge.
The Druze faith further split from Isma'ilism as it developed its own unique doctrines, and finally separated from both Ismāʿīlīsm and Islam altogether; these include the belief that the Imam Al-Ḥākim bi-Amr Allāh was God incarnate. Hamza ibn Ali ibn Ahmad is considered the founder of the Druze faith and the primary author of the Druze manuscripts, he proclaimed that God became flesh, assumed a human nature, and became a man in the form of al-Hakim bi-Amr Allah. Historian David R. W. Bryer defines the Druzes as ghulat of Isma'ilism, since they exaggerated the cult of the caliph al-Hakim bi-Amr Allah and considered him divine; he also defines the Druzes as a religion that deviated from Islam. He also added that as a result of this deviation, the Druze faith "seems as different from Islam as Islam is from Christianity or Christianity is from Judaism". The incarnation of Jesus is the central Christian doctrine that God became flesh, assumed a human nature, and became a man in the form of Jesus, the Son of God and the second person of the Trinity. This foundational Christian position holds that the divine nature of the Son of God was perfectly united with human nature in one divine Person, Jesus, making him both truly God and truly human. The theological term for this is hypostatic union: the second person of the Trinity, God the Son, became flesh when he was miraculously conceived in the womb of the Virgin Mary.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.